Asterias Biotherapeutics to Present at Biotech Showcase™ 2016

06 Jan, 2016, 07:00 ET from Asterias Biotherapeutics, Inc.

FREMONT, Calif., Jan. 6, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and CEO of Asterias, will present at the Biotech Showcase™ 2016 Conference in San Francisco on Tuesday, January 12, 2016 at 9:00 AM PT/12:00 PM ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://asteriasbiotherapeutics.com/events-presentations/. The replay will be available for approximately 90 days after the event.

To schedule a meeting with Asterias Biotherapeutics at this conference, contact Investor Relations at InvestorRelations@asteriasbio.com.

About the Biotech Showcase

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential strategics in one place during the course of one of the industry's largest annual healthcare investor conferences.  The event is expected to bring together 2,100+ attendees representing the life science industry's most enterprising and pioneering biotech companies and major players in the drug development arena.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a biotechnology company in the emerging field of regenerative medicine. The Company's proprietary, industry-leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines.

 

SOURCE Asterias Biotherapeutics, Inc.



RELATED LINKS

http://www.asteriasbiotherapeutics.com